

## General Tumor Board

Jointly Provided by Newark Beth Israel Medical Center and Rutgers Biomedical and Health Sciences

### ***Rectosigmoid cancer (2 cases)***

**NBIMC – Virtual Meeting (see access instructions below)**

**Friday, October 7, 2022**

**8:00 am – 9:00 am**

#### **Maya Shah, M.D.**

Attending, Hematology/Oncology  
Newark Beth Israel Medical Center, Newark, New Jersey

#### **Jordonna Brown, M.B.B.S.**

Oncology Fellow, Newark Beth Israel Medical Center  
Newark, New Jersey

#### **Objectives**

At the conclusion of this activity, participants should be better able to:

- Effectively manage oncology cases in a multidisciplinary fashion
- Plan treatment for previously untreated patients according to national treatment standards
- Improve patterns of care using Standard Treatment Protocols in cancer

#### **Target Audience**

This activity is designed for surgeons, medical and radiation oncologists, internists, advanced practice nurses, physician assistants, nurses, fellows and residents involved in the management of patients with cancer.

#### **Accreditation**



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Rutgers Biomedical and Health Sciences and Newark Beth Israel Medical Center. Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Physicians:** Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses:** This activity is awarded 1 contact hour. (60-minute CH)

#### **Disclosure Declarations**

Dr. Shah and Dr. Brown have no relevant financial relationships with ineligible companies to disclose.

Speakers are required to disclose discussion of off-label/investigational uses of commercial products/devices in their presentation. These disclosures will be made to the audience at the time of the activity.

#### **Planning Committee:**

Dr. A. Cohen (Content Reviewer), Dr. C. Cathcart, Dr. K. Clarke, C. Kosmides, APN have no relevant financial relationships with ineligible companies to disclose.

**Meeting access:** This conference is protected. Please contact [nadine.walker@rwjbh.org](mailto:nadine.walker@rwjbh.org) to gain access.